+

WO2009088125A1 - Composition pour des articles hygiéniques comprenant un immunoadjuvant mucosal et son procédé de préparation - Google Patents

Composition pour des articles hygiéniques comprenant un immunoadjuvant mucosal et son procédé de préparation Download PDF

Info

Publication number
WO2009088125A1
WO2009088125A1 PCT/KR2008/002394 KR2008002394W WO2009088125A1 WO 2009088125 A1 WO2009088125 A1 WO 2009088125A1 KR 2008002394 W KR2008002394 W KR 2008002394W WO 2009088125 A1 WO2009088125 A1 WO 2009088125A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaginal
mucosal
mistletoe lectin
women
cleansing
Prior art date
Application number
PCT/KR2008/002394
Other languages
English (en)
Inventor
Hwan-Joon Jung
Se-Joong Kim
Seung-Hoon Yang
Original Assignee
Didimbiotech Co, . Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Didimbiotech Co, . Ltd. filed Critical Didimbiotech Co, . Ltd.
Publication of WO2009088125A1 publication Critical patent/WO2009088125A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a composition for sanitary supplies for women (e.g., vaginal cleansing solution, vulval cleansing solution, vaginal tablet, etc.) comprising a mucosal immunoadjuvant, sanitary supplies for women comprising the composition and a preparation method thereof.
  • sanitary supplies for women e.g., vaginal cleansing solution, vulval cleansing solution, vaginal tablet, etc.
  • sanitary supplies for women comprising the composition and a preparation method thereof.
  • the female genitourinary system including uterus, vagina, vulva, urethra, etc. is susceptible to infection from outside due to its intrinsic anatomical, physiological and functional features.
  • the vagina is located deep in the body and, thus, is warm and moist. Accordingly, bacteria or fungi, which are main causes of vaginitis, may proliferate and lead to diseases. Therefore, it is preferable to always keep the vagina clean to prevent from bacterial infection.
  • the female reproductive organ may be easily infected by germs through the mucosa during sexual intercourse. It is reported that chronic inflammation may be induced when a contraceptive device is placed inside the uterus for a long period of time (Wagenlehner, et al., Clin. Microbiol. Infect. 9(8), 881-5, 2003). And, during the introduction a medical device into the body or delivery of mammals, the corresponding mucous membrane can be often damaged, which can be at high risk of infection and inflammation.
  • Inflammation in the genitourinary system is one of the commonest diseases found in women.
  • the inflammation may be caused by bacteria, parasites or viruses. Patients suffer from pruritis, severe inflammation and foul odor.
  • the papillomavirus infection is very closely related to cervical cancer. Therefore, it is very important to avoid development into a fatal complication through adequate prevention, diagnosis and treatment.
  • the most common infections of the female genitalia include bacterial vaginosis, trichomonal vaginitis, candidal vulvovaginitis and vaginitis, chronic vulval candidiasis, general inflammatory vaginitis, atrophic vaginitis, cervical vaginitis, and the like.
  • bacterial vaginosis e.g., vulva, vagina, cervix, etc.
  • trichomonal vaginitis e.g., candidal vulvovaginitis and vaginitis
  • chronic vulval candidiasis e.g., chronic vulval candidiasis
  • general inflammatory vaginitis e.g., atrophic vaginitis, cervical vaginitis, and the like.
  • Vaginal cleansing solution or vulval cleansing solution is frequently used to prevent women's diseases and remove foul odors.
  • solution or lotion type cleansers used to prevent vaginitis, which comprise sulfonated fatty acid or distilled lauryl alcohol and an emollient, a thickener, a nutrient, a foaming agent, an organic disinfectant, and so forth.
  • Another example is one mainly consisting of a surfactant and/or povidone iodide.
  • the synthetic disinfectant povidone iodide is known to be effective in preventing and treating candidal vaginitis, trichomonal vaginitis and other vaginal infections.
  • tablet, lotion, cream, ointment or solution type vaginal products comprising antibiotics as active ingredient to prevent or treat the diseases are used.
  • the risk of infection by pathogenic bacteria and inflammation increases when the body's immune system is weakened. Accordingly, in order to prevent or treat the pathogen infection, it is necessary to enhance resistance against pathogens, microorganisms, viruses or cancer cells by activating the immunoregulatory system of the body.
  • One way of activating the immunoregulatory system is immuno- augmentation through the mucous membrane.
  • the mucous membranes are originated from the endoderm and are distributed over the organs involved in absorption and secretion. They line various body cavities that are exposed to the external environment and internal organs: respiratory organs including the nostrils, the airway and the tonsil; digestive organs including the small intestine and the rectum; and reproductive organs.
  • the mucous cells perform the primary defensive function against pathogens from external environment at the very forefront. As such, the immunity through mucous cells is very important for the defense of the body.
  • mucosal immunoadjuvants examples include ⁇ -glucan, CT (cholera toxin) B- subunit, E. coli LT (heat-labile toxin), LPS (lipopoly saccharide) including pertussis toxin, MPL (monophosphoryl lipid A), CgP ODN (oligodeoxynucleotides containing unmethylated dinucleotides), an aluminum salt, elethero (Acanthopanax Senticosus) extract, a mistletoe extract and alum.
  • CT cholera toxin
  • E. coli LT heat-labile toxin
  • LPS lipopoly saccharide
  • MPL monophosphoryl lipid A
  • CgP ODN oligodeoxynucleotides containing unmethylated dinucleotides
  • an aluminum salt elethero (Acanthopanax Senticosus) extract, a mistletoe extract and
  • an object of the present invention is to provide sanitary supplies for women which, in addition to their inherent function of cleansing, enhance the body's immunity, thereby providing superior stability and enabling the body to protect itself from harmful microorganisms in the vagina.
  • the present inventors have achieved the aforesaid object by providing a composition for sanitary supplies for women, such as vaginal cleansing solution, comprising a mucosal immunoadjuvant.
  • a composition for sanitary supplies for women such as vaginal cleansing solution
  • a mucosal immunoadjuvant a composition for sanitary supplies for women, such as vaginal cleansing solution
  • Introduction of immunoadjuvants to sanitary supplies for women such as cleanser, vaginal tablet, etc. has never been attempted before.
  • the present invention provides a safer and more convenient way of enhancing basic immunity, while providing the intrinsic functions of sanitary supplies such as cleansing, sterilization, and the like.
  • the present invention provides a composition for sanitary supplies for women comprising a mucosal immunoadjuvant and a preparation method thereof.
  • the present invention also provides sanitary supplies for women prepared from a composition comprising a mucosal immunoadjuvant.
  • the present invention provides a cleansing solution for the urinogenital organs of women in which a suitable amount of an immunoadjuvant that induces mucosal immunity is mixed with a vaginal cleansing solution or a vulval cleansing solution.
  • a cleansing solution provides the effect of preventing venereal diseases, infections and various diseases by enhancing basic immunity through inducing mucosal immunity, in addition to its intrinsic functions as cleanser.
  • an immunoadjuvant in the vaginal tablet, lotion, cream, ointment or solution applied to prevent or treat infection in the vagina, the stimulation to the mucous membrane is maximized and the mucosal immunity and the systemic immunity are enhanced.
  • the present invention is based on the experimental results that, in the case of applying a vaginal cleansing solution prepared by adding a substance known to have an effect of enhancing the stimulation of mucosal immunity to the vaginas of mice, the ratio of B -/T -cell differentiation and the differentiation potential of T cells increase in splenocytes, and epithelial cells in the urinogenital organs are activated to produce a large amount of immunoglobulins and enhance the secretion of ThI type cytokines, thereby enhancing immunity, as compared to the control group without the substance that enhances mucosal immunity.
  • the present inventors added mucosal immunoadjuvants to the already known vaginal cleansing solutions and injected each of them into the vaginas of female BALB/C mice.
  • the mucosal immunoadjuvants were ⁇ -glucan, CT B-subunit, E. coli LT, LPS including pertussis toxin, CgP ODN, an aluminum salt, an eleuthero extract, mistletoe lectin, mistletoe lectin B-chain and cocktails thereof.
  • the mucosal immunoadjuvants were added to commercially available vaginal cleansing solution and vulval cleansing solution (e.g., Cepee®, Samuel Cleanser®).
  • test groups treated with the cleansing solutions including the mucosal immuno- adjuvant exhibited twice or higher B-cell and T-cell activity, as compared to the control group treated with the cleansing solution including a phosphate buffer instead of mucosal immunoadjuvant.
  • test groups treated with the cleansing solution including the mucosal immunoadjuvants or cocktails thereof showed overall enhancement in immunity with at least 1:64,000 of IgG titration in serum, at least 1: 16,000 of IgG titration in mucosal cleansing solution samples, and at least 1:8,000 of IgA titration in mucosal cleansing solution samples of the urinary organ, as compared to the control group treated with the cleansing solution including a phosphate buffer instead of mucosal immunoadjuvant.
  • ThI type cytokine such as TNF- ⁇ , IL-2 and
  • a vaginal or vulval cleansing composition comprising a mucosal immunoadjuvant.
  • the immunoadjuvant is selected from the group consisting of ⁇ -glucan, CT B-subunit, E. coli LT, pertussis toxin, LPS, MPL, CgP ODN, an aluminum salt, an eleuthero extract, European mistletoe lectin, European mistletoe lectin B-chain, a Korean mistletoe extract, Korean mistletoe lectin, Korean mistletoe
  • the immunoadjuvant is selected from the group consisting of CT B-subunit, European mistletoe lectin, Korean mistletoe lectin, European mistletoe lectin and CpG ODN, Korean mistletoe lectin and CpG ODN, LPS and Korean mistletoe lectin, CT B-subunit and Korean mistletoe lectin, and ⁇ -glucan and Korean mistletoe lectin.
  • a preparation method of a vaginal or vulval cleansing composition comprising adding a mucosal immunoadjuvant.
  • a vaginal or vulval cleansing solution comprising a composition according to any of [1] to [3].
  • a vaginal product or sanitary supply for women comprising an immunoadjuvant capable of inducing mucosal immunity.
  • vaginal product or sanitary supply for women according to [6], wherein the vaginal product or sanitary supply for women is in the form selected from the group consisting of vaginal tablet, lotion, cream, ointment and solution.
  • the cleansing solution of the present invention induces mucosal immunity by stimulating the female genitalia, thereby resulting in nonspecific immunity, which is spread to all the mucosal area in the body, including serum, oral mucous membranes, ocular mucous membranes, nasal mucous membranes, gastrointestinal mucous membranes, respiratory mucous membranes, urinary mucous membranes, and genital mucous membranes. Accordingly, the resistance to initial infection by pathogens is enhanced and the initial immunity against respiratory infectious diseases, food-borne infectious diseases, anal and rectal infectious diseases, and urinary infectious diseases is enhanced.
  • the present invention is effective in initially blocking infectious diseases caused by most microorganisms and a few viruses and, thus, is valuable for non-drug products. Further, the present invention can provide prevention against the pandemic infectious diseases, including AIDS, SARS and aviation flu, and keep the genitalia healthy.
  • the mucosal immunoadjuvant added to the sanitary supplies for women and vaginal products including vaginal cleansing solution, vulval cleansing solution, vaginal tablet, etc. may be any one known in the related art, as long as the advantageous effect provided by the present invention is attained.
  • Examples include ⁇ -glucan, CT B- subunit, E. coli LT, LPS including pertussis toxin, MPL, CgP ODN, an aluminum salt, an eleuthero extract, European mistletoe lectin, European mistletoe lectin B-chain, a Korean mistletoe extract, Korean mistletoe lectin, Korean mistletoe lectin B-chain and cocktails thereof.
  • a mistletoe extract, a mistletoe lectin or a cocktail thereof with other immunoadjuvants are preferred.
  • composition provided by the present invention may be included in any known or commercially available sanitary supplies for women, as long as the advantageous effect provided by the present invention is attained.
  • vaginal cleansing composition of the present invention may be in various forms.
  • the composition may be in liquid form, such as solution, suspension, emulsion, etc., and may be prepared by adding a solubilizer, an emulsifier, a buffer for pH control, etc. to sterilized water.
  • the composition may further comprise an excipient in addition to the active ingredient.
  • the excipient may be a binder, an anticaking agent, a disintegrant, a vehicle, a solubilizer, a dispersing agent, a stabilizer, a suspending agent, a pigment, a fragrance, a buffer, a preservative, a solubilizer, a tonifier, a matrix, a filler, a lubricant, a surfactant, etc.
  • polysaccharide, oligosaccharide, oil and fat, protein, vitamin, steroid, hormone, low alcohol, polyalcohol, vasodilator, spermicide, bactericide, antiviral agent, etc. may be included. These may be included in an amount which is normally used in the pharmaceutical field.
  • the composition according to the present invention may comprise the mucosal im- munoadjuvant in an amount from 0.1 % by weight to 15 % by weight, preferably from 3 % by weight to 10 % by weight, based on the total weight of the composition.
  • the composition of the present invention is administered at a pharmaceutically effective dosage, which may be determined depending on the disease and severity thereof, age and sex of the patient, activity of the drug, sensitivity to the drug, time and route of administration, discharge ratio, duration of treatment, concomitant use of other drugs, and other well-known factors. It is important to determine the dosage that can lead to the best effect with the smallest amount, which can be readily performed by those skilled in the art.
  • Another object of the present invention is to provide a preparation method of sanitary supplies for women and vaginal medications including vaginal cleansing solution, vulval cleansing solution, vaginal tablet, etc. by adding an immunoadjuvant capable of inducing mucosal immunity.
  • the sanitary supplies for women and vaginal medications used in the present invention may be already known ones and the mucosal immunoadjuvant is added in an appropriate manner according to the product type.
  • the composition of the present invention and the sanitary supplies for women comprising the same provide the effect of preventing and treating vaginal infection, as well as providing the intrinsic functions of sanitary supplies.
  • pandemic infectious diseases such as AIDS, SARS, avian flu, etc. may be prevented, or the genitalia can be maintained healthy.
  • FIG. 1 is a drawing illustrating the ratio of B-/T-cell differentiation in the splenocytes of mice, vaginas of which were stimulated with the vaginal cleansing composition of the present invention.
  • FIG. 2 is a drawing illustrating the differentiation potential of T-cells in the splenocytes of mice, vaginas of which were stimulated with the vaginal cleansing composition of the present invention.
  • FIG. 3 is a drawing illustrating the concentration of IgG and IgA in sera of mice, vaginas of which were stimulated with the vaginal cleansing composition of the present invention.
  • FIG. 40 is illustrating the concentration of IgG and IgA in sera of mice, vaginas of which were stimulated with the vaginal cleansing composition of the present invention.
  • FIG. 4 is a drawing illustrating the concentration of IgG and IgA in wash samples of urinary and reproductive organs of mice, vaginas of which were stimulated with the vaginal cleansing composition of the present invention.
  • FIG. 5 is a drawing illustrating the concentration of TNF- ⁇ and IL-2 in sera of mice, vaginas of which were stimulated with the vaginal cleansing composition of the present invention.
  • FIG. 6 is a drawing illustrating the concentration of INF- ⁇ in sera of mice, vaginas of which were stimulated with the vaginal cleansing composition of the present invention.
  • vaginal cleansing solutions including a mucosal immunoadjuvant were prepared as in Table 1. [46] [ Table 1 ]
  • compositions of vaginal cleansing composition [47] Compositions of vaginal cleansing composition
  • cocktail compositions comprising more than one mucosal immunoadjuvant were prepared.
  • the compositions are given in Table 2.
  • the single immunoadjuvants or cocktail mixtures listed in Table 2 were directly mixed with the commercially available cleansing solutions (Cepee®,ssen Cleanser®), or the mucosal immunoadjuvants were dissolved in purified water and then mixed with the cleansing compositions.
  • the mucosal immunoadjuvants were either commercially purchased or prepared according to the method described in Korean Patent Application Nos. 10-1996-5732, 10-2004-31109 or 10-1999-41288.
  • Example 2 Examination of differentiation potential of B-/T-cells of mouse splenocytes using FACScan
  • mice were stimulated by washing with each of 500 ⁇ L of the cleansing solutions comprising 0.01 % of each ⁇ -glucan, CT B-subunit, CpG ODN, LPS, aluminum salt, mistletoe lectin, and mistletoe lectin B-chain using a sterilized pipette. Such treatment was carried out for 15 days (once a day).
  • the control group was treated similarly using a phosphate buffer (PBS) instead of the mucosal immuno- adjuvant.
  • PBS phosphate buffer
  • the mice were sacrificed, and splenocytes were isolated from the spleens. Then, the ration of B-/T-cell differentiation was observed using antibodies by FACScan.
  • the test groups treated with the cleansing solutions containing the mucosal immunoadjuvants showed twice or higher ratio than the control group (see FIG. 1).
  • Example 3 Examination of differentiation potential of T-cells from mouse splenocytes using FACScan
  • Example 2 differentiation potential of T-cells was examined. More CD3 was observed since the response was a nonspecific immune response (see FIG. 2). If antigens had been administered together, more CD4 or CD8 would have been observed than CD3. To conclude, the treatment of the vaginal mucosal membranes with the cleansing solutions comprising the immunoadjuvants enhanced nonspecific immunity, and the differentiation potential of T-cells increased on the whole. Accordingly, it is thought that immunity against various antigens or pathogens was activated.
  • mice vaginas of which were stimulated with the cleansing solutions comprising the immunoadjuvants showed at least 1:64,000 of IgG titration in serum, and at least 1: 16,000 of IgG titration in the mucosal cleansing solution samples, as compared to the control group.
  • IgA was not observed in the serum, and IgA titration in the mucosal cleansing solution samples excluding serum was at least 1:8,000 (see FIG. 3 and FIG. 4).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une composition pour des articles hygiéniques pour les femmes (solution de nettoyage vaginale, solution de nettoyage de la vulve, comprimé vaginal, etc.) comprenant un immunoadjuvant mucosal, et sur son procédé de préparation. L'invention porte en outre sur des articles hygiéniques pour les femmes comprenant l'immunoadjuvant mucosal. La composition de la présente invention améliore l'immunité contre les infections et maladies en induisant une immunité mucosale dans le système génito-urinaire des femmes, qui est susceptible d'être exposé à des infections, fournissant par là également un effet de prévention contre des infections et des maladies, ainsi que les fonctions intrinsèques des articles hygiéniques pour les femmes.
PCT/KR2008/002394 2008-01-08 2008-04-28 Composition pour des articles hygiéniques comprenant un immunoadjuvant mucosal et son procédé de préparation WO2009088125A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0002359 2008-01-08
KR1020080002359A KR101012507B1 (ko) 2008-01-08 2008-01-08 점막면역 유도능이 있는 면역증강제를 포함하는 여성위생용품용 조성물 및 그 제조방법

Publications (1)

Publication Number Publication Date
WO2009088125A1 true WO2009088125A1 (fr) 2009-07-16

Family

ID=39823232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/002394 WO2009088125A1 (fr) 2008-01-08 2008-04-28 Composition pour des articles hygiéniques comprenant un immunoadjuvant mucosal et son procédé de préparation

Country Status (2)

Country Link
KR (1) KR101012507B1 (fr)
WO (1) WO2009088125A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014027958A1 (fr) * 2012-08-14 2014-02-20 Nanyang Technological University Méthodes antivirales et utilisation d'un agent antiviral

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101125758B1 (ko) * 2009-03-18 2012-03-27 정산생명공학 주식회사 여성 국부 청결용 세정제 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011701A1 (fr) * 1993-10-26 1995-05-04 Syntello, Inc. Inhibition de l'infection des muqueuses par le vih
KR100614679B1 (ko) * 2004-03-19 2006-08-21 보람제약주식회사 한국산 겨우살이 추출물을 유효성분으로 함유하는점막면역 증진용 세척제 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040072954A (ko) * 2003-02-11 2004-08-19 김종배 경구용 면역증강제의 활성을 가지는 한국산 겨우살이 렉틴성분

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011701A1 (fr) * 1993-10-26 1995-05-04 Syntello, Inc. Inhibition de l'infection des muqueuses par le vih
KR100614679B1 (ko) * 2004-03-19 2006-08-21 보람제약주식회사 한국산 겨우살이 추출물을 유효성분으로 함유하는점막면역 증진용 세척제 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEBORAH TIEN ET AL.: "In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials", AIDS RES HUM RETROVIRUSES., vol. 21, no. 10, 1 October 2005 (2005-10-01), pages 845 - 853 *
SAMUEL BARON ET AL.: "Practical prevention of vaginal and rectal transmission ofHIV by adapting the oral defense: use of commercial lubricants", AIDS RES HUM RETROVIRUSES., vol. 17, no. 11, 20 July 2001 (2001-07-20), pages 997 - 1002, XP001203711, DOI: doi:10.1089/088922201300343672 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014027958A1 (fr) * 2012-08-14 2014-02-20 Nanyang Technological University Méthodes antivirales et utilisation d'un agent antiviral

Also Published As

Publication number Publication date
KR20080070525A (ko) 2008-07-30
KR101012507B1 (ko) 2011-02-08

Similar Documents

Publication Publication Date Title
JP5065246B2 (ja) 腟の微生物叢と腟の酸性を調節して維持する組成物と方法
Amaral et al. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel
EP3233098B1 (fr) Transplantation de sécrétions cervico-vaginales pour traiter la vaginose bactérienne
JP2019059950A (ja) 潤滑剤配合物
WO2011041938A1 (fr) Composition comprenant de l'acide benzoïque en association avec des conservateurs acides organiques comme composants actifs et son utilisation
CN103157095B (zh) 芸豆植物凝集素在制备人用药物中的应用及其药物组合物
CN105232526B (zh) 含儿茶素的药物在制备抑菌药物中的用途
WO2008147049A1 (fr) Composition lubrifiante renfermant des agents qui induisent l'immunité des muqueuses et procédé de préparation correspondant
WO2009088125A1 (fr) Composition pour des articles hygiéniques comprenant un immunoadjuvant mucosal et son procédé de préparation
CN111012902B (zh) 女用抗菌避孕养护凝胶及其制备方法
CN108404111A (zh) 一种以芸豆植物凝集素为主要成分的抑菌抗病毒制剂
CN110354224A (zh) 一种用于阴道黏膜抑菌、止痒、祛味的中药凝胶组合物
WO2000015192A1 (fr) Procedes et substances pour gels contraceptifs bioadhesifs
RU2557957C1 (ru) Способ лечения больных с хроническим эндометритом и трубно перитонеальным фактором бесплодия
Trottier et al. Safety, tolerance and acceptability of the Invisible Condom® and its vaginal applicator in healthy women and their male sexual partners
RU2320319C1 (ru) Суппозитории вагинальные
CN101172159A (zh) 酸性生物粘附热敏凝胶剂及其制法和用途
RU2240781C1 (ru) Способ лечения воспалительных процессов вульвы и влагалища
CN113230390A (zh) 一种组合物、阴道洗剂及其在妇科黏膜损伤修复中的应用
RU2361595C1 (ru) Способ лечения осложненного урогенитального хламидиоза
DE COSTA Infections of the vagina and vulva
Mbopi-Keou et al. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom® formulations in women from Cameroon
Smith Vaginal thrush: over-the-counter management in the pharmacy
RU2278672C2 (ru) Способ лечения хронических воспалительных заболеваний шейки матки и влагалища
SCHNEIDER et al. Vaginitis in adolescent girls

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08753203

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08753203

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载